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Abstract
Background: Cisplatin has been widely used to treat head and neck cancer. One of the clinical
limitations with this treatment, however, is that tumors that are initially responsive to cisplatin later
acquire resistance. We have recently shown that a subset of head and neck cancer cell lines has a
defective Fanconi anemia DNA damage response pathway and this defect correlates to cisplatin
sensitivity. We have also shown that the histone deacetylase inhibitor phenylbutyrate sensitize
human cells to cisplatin. In this study we explored whether phenylbutyrate may sensitize head and
neck cancer cells by interfering with the Fanconi anemia pathway.
Results: We found that the phenylbutyrate sensitizes head and neck cancer cell lines to cisplatin.
This sensitization by phenylbutyrate correlated to a significant decrease in the formation of
cisplatin-induced FANCD2 nuclear foci, which is a functional read out of the Fanconi anemia and
BRCA (FA/BRCA) pathway. This abrogation of the FA/BRCA pathway by phenylbutyrate was not
due to loss of FANCD2 monoubiquitylation but rather correlated to a phenylbutyrate-mediated
reduction in the expression of the BRCA1 protein. Furthermore, we found that cancer cells
defective in the FA pathway were also sensitized to cisplatin by phenylbutyrate suggesting that
phenylbutyrate targets additional pathways.
Conclusion: The results from this study suggest that phenylbutyrate may have therapeutic utility
as a cisplatin sensitizer in head and neck cancer by inhibiting the FA/BRCA pathway through the
down regulation of BRCA1 as well as by an FA/BRCA-independent mechanism.
Background
Cisplatin is a widely used chemotherapeutic agent used
against many different types of tumors [1,2]. However,
the variable tumor responses limit the usefulness of cispl-
atin as a therapeutic agent. It has been shown that the var-
iation in cisplatin response in ovarian cancer is linked to
the status of the FA/BRCA pathway [3]. This pathway is
involved in the processing of cisplatin-induced DNA dam-
age and cells defective in the FA/BRCA pathway are hyper-
sensitive to cisplatin and other agents that introduce
interstrand DNA cross-links [4,5]. We recently showed
that cisplatin sensitivity in head and neck cancer may also
be linked to the FA/BRCA pathway since cisplatin-sensi-
tive head and neck cancer cell lines were found to be
defective in the formation of FANCD2 nuclear DNA repair
foci [6]. This defect was corrected by exogenously express-
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ing wild-type BRCA1 in these cells suggesting that attenu-
ated expression or mutations of the BRCA1 gene may be
responsible for the failure of the FA/BRCA pathway to
launch an appropriate response in these cells which
would explain their cisplatin hypersensitivity [6].
Cisplatin induces intrastrand DNA cross-links, which con-
stitutes about 85–90% of all lesions, and interstrand DNA
cross-links contributing about 1–2% to the total lesion
burden [7-9]. It is thought that because of its high abun-
dance, the intrastrand DNA cross-links may be the major
class of lesions responsible for the toxic effects of cispla-
tin. However, due to its severe inhibiting effect on replica-
tion and transcription and the complicated nature of its
repair, the lower yield-forming interstrand DNA cross-
links may greatly contribute to the toxicity of cisplatin [7-
9]. While intrastrand DNA cross-links are repaired prima-
rily by the nucleotide excision repair pathway, interstrand
DNA cross-links are repaired by a combination of repair
enzymes from both nucleotide excision repair and
homologous recombination [7]. In addition, translesion
DNA synthesis polymerases [10,11] and the FA/BRCA
pathway [3,12,13] contribute to the tolerance of inter-
strand cross-links although the mechanisms responsible
for this protection are not understood in detail.
While cisplatin works well as a first-line therapy with an
estimated 50% response rate, it is less effective if the
tumor reoccurs [1]. As most tumors are heterogeneous,
harboring cancer cells with a range of cisplatin sensitivi-
ties, cisplatin will preferentially kill off the cisplatin-sensi-
tive cancer cells in the tumor while the surviving cisplatin-
resistant cells will repopulate the tumor. This will make
subsequent cisplatin treatments ineffective on reoccurring
tumors [3]. Another drawback of cisplatin therapy is its
dose-dependent toxicities. Thus, efforts are needed to
explore whether there are agents that could be combined
with cisplatin to overcome the cisplatin resistance of reoc-
curring tumors and to lower the doses of cisplatin needed
for a therapeutic response.
We and others have previously shown that histone
deacetylase (HDAC) inhibitors can sensitize human cells
to cisplatin [14,15]. The mechanism for this sensitization
is not clearly understood but may involve the down-regu-
lation of the apoptosis antagonist Bcl-XL and the DNA
double-strand break repair protein DNA-PK [16]. The
HDAC inhibitor phenylbutyrate has shown a good clini-
cal safety record when used to treat urea cycle disorders
and cystic fibrosis [17-19]. Furthermore, laboratory stud-
ies have shown that phenylbutyrate has potential anti-
tumor activity by specifically killing tumor cells [20] and
by blocking the invasiveness of metastatic cancer cells
[21].
In this study, we investigated whether phenylbutyrate
could sensitize head and neck cancer cells to cisplatin.
Our results show that three relatively cisplatin-resistant
head and neck cancer cell lines were sensitized to cisplatin
when they were pretreated with phenylbutyrate. The
mechanism for sensitization may involve the abrogation
of the FA/BRCA pathway since phenylbutyrate abrogated
the formation of FANCD2 repair foci following cisplatin
treatment and this abrogation correlated to a phenylbu-
tyrate-mediated decrease in BRCA1 expression. In addi-
tion, phenylbutyrate sensitized one head and neck cancer
cell line with a defective FA/BRCA1 pathway to cisplatin
suggesting that phenylbutyrate targets multiple pathways
that normally protect cells against cisplatin.
Results
Phenylbutyrate sensitizes head and neck cancer cells to 
cisplatin
To investigate whether phenylbutyrate (PB) sensitizes
head and neck cancer cells to cisplatin, three relative cispl-
atin-resistant head and neck cancer cell lines all expressing
wild-type p53 (UM-SCC-1, -6, -25) were used. Cells were
treated with 2 mM phenylbutyrate for 5 days, 5 μM cispl-
atin for 3 days or the combination of the two with cispla-
tin added on day three. The doses of phenylbutyrate and
cisplatin used were chosen because they are clinically
achievable. The effects these treatments had on the three
cell lines were first analyzed by measuring viability/prolif-
eration using the WST-1 assay. This assay is based on the
reduction of the WST-1 reagent by viable cells to produces
a soluble formazan salt that can be quantitated with an
ELISA plate reader. Since the absorbance correlates with
the number of viable cells in the sample, the readout is
affected by cell death and inhibition of proliferation dur-
ing the treatment period. When the three head and neck
cancer cell lines were treated with either phenylbutyrate or
cisplatin as single agents, viability/proliferation was
reduced by 0–10% and 20–30%, respectively (Fig. 1A).
When the two treatments were combined, the viability/
proliferation was reduced by about 50%, which is more
then an additive effect of each agent alone.
Since the WST-1 assay does not distinguish between loss
of viability and inhibition of proliferation, we next inves-
tigated whether phenylbutyrate could sensitize the cells to
cisplatin-induced apoptosis. Cells were treated as for the
WST-1 assay described above, collected, fixed and stained
with propidium iodide (PI) for the determination of
apoptosis using flow cytometry. Treatment with phenyl-
butyrate alone only marginally increased the percentage
of apoptotic cells over mock-treated cells while cisplatin
treatment increased apoptosis by 20–30% over control
cells (Fig. 1B). When cells were pretreated with phenylbu-
tyrate for 48 hours before adding cisplatin, apoptosis wasMolecular Cancer 2008, 7:24 http://www.molecular-cancer.com/content/7/1/24
Page 3 of 9
(page number not for citation purposes)
increased by 40–55% over mock-treated cells suggesting
that the effect was more than additive.
Finally, we assessed the potential phenylbutyrate-induced
sensitization of the cells to cisplatin using the clonogenic
assay. This assay was only applicable to the UM-SCC-1 cell
line since the other two cell lines failed to form colonies
under our culture conditions. We found that phenylbu-
tyrate did not significantly reduce the clonogenic survival
of the UM-SCC-1 cells while cisplatin treatment reduced
clonogenic survival by about 20%. When the two treat-
ments were combined, we observed a much more dra-
matic cell kill than adding up the cell killing effects of the
two drugs alone. Taken together, all three cell survival
assays used suggest that phenylbutyrate sensitizes head
and neck cancer cell lines to cisplatin.
Phenylbutyrate attenuates the formation of cisplatin-
induced FANCD2 nuclear foci
What may be the mechanism by which phenylbutyrate
sensitizes these head and neck cancer cell lines to cispla-
tin? Since cisplatin induces interstrand DNA cross-links
and cells deficient in the FA/BRCA pathway are hypersen-
sitive to cisplatin we next explored whether the cisplatin-
sensitizing effect of phenylbutyrate correlated to a phenyl-
butyrate-mediated abrogation of the FA/BRCA pathway.
The FA/BRCA response pathway is an important pathway
that is thought to orchestrate the processing of DNA inter-
strand cross-links [4,5]. A functional readout of an acti-
vated FA/BRCA pathway is the formation of microscopic
aggregates of FANCD2 proteins in nuclei, most likely rep-
resenting sites of DNA damage. To investigate whether
phenylbutyrate may interfere with the FA/BRCA response
pathway and block the formation of FANCD2 nuclear foci
after cisplatin treatment, the three different head and neck
cancer cell lines were treated with phenylbutyrate, cispla-
tin or the combination of the two agents. Cells were then
fixed and stained with anti-FANCD2 specific antibodies.
Fluorescence microscopic inspection of the stained cells
showed that cisplatin induced FANCD2 nuclear foci in
about 45% of the cells analyzed while phenylbutyrate did
not induce any FANCD2 foci over mock-treated control
cells (Fig. 2). When the two agents were combined it was
clear that phenylbutyrate significantly reduced the
number of cells containing cisplatin-induced FANCD2
nuclear foci. Since phenylbutyrate did not affect viability
or proliferation of the different cell lines (see Fig. 1A), we
do not think the lowering of the number of cells with cis-
platin-induced FANCD2 foci by phenylbutyrate is due to
a redistribution of the cells in the cell cycle due to the acti-
vation of a cell cycle arrest. These results suggest that phe-
nylbutyrate sensitizes head and neck cancer cells to
cisplatin by abrogating the FA/BRCA pathway.
Phenylbutyrate sensitizes cisplatin-resistant head and neck cancer cell lines Figure 1
Phenylbutyrate sensitizes cisplatin-resistant head and neck cancer cell lines. (A) The head and neck cancer cell lines UM-SCC-
1, -6 and -25 were treated with 2 mM phenylbutyrate (PB) for 5 days, 5 μM cisplatin for 3 days or pretreated with phenylbu-
tyrate for 48 hrs followed by the addition of 5 μM cisplatin for 3 days. After treatments, cell viability/proliferation from each 
cell sample was determined using the WST-1 assay and values are expressed as a percentage of control cells. Error bars repre-
sent the standard error of the mean of triplicate samples. (B) Cells treated as in (A) were collected (both floating and attached 
cells), fixed and stained with propidium iodide and cells with sub-G1 DNA content were counted as apoptotic cells. The values 
are expressed as percentage of sub-G1 cells of total cells analyzed and error bars represent the standard error of the mean of 
triplicate samples. (C) Adherent UM-SCC-1 cells treated as in (A) were trypsinized and seeded at low densities in fresh media 
and incubated for 14 days. Clonogenic survival (%) is expressed as the fraction of surviving cells compared to control cells and 
expressed as a percentage with error bars represent the standard error of the mean of triplicate samples.
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Phenylbutyrate attenuates BRCA1 expression
Because FANCD2 monoubiquitylation is required for the
formation of FANCD2 foci, we next investigated whether
phenylbutyrate may affect the cisplatin-induced monou-
biquitylation of FANCD2. The three head and neck cancer
cell lines were treated with phenylbutyrate, cisplatin or
the combination of the two and the induction of monou-
biquitylation of FANCD2 was evaluated using Western
blot. It was found that cisplatin induced monoubiquityla-
tion of FANCD2 regardless of whether the cells had been
pretreated with phenylbutyrate or not (Fig 3). Thus, the
phenylbutyrate-mediated abrogation of cisplatin-induced
FANCD2 foci formation was not due to a loss of FANCD2
monoubiquitylation.
It has been shown that in addition to monoubiquitylation
the formation of FANCD2 nuclear foci following cisplatin
treatment requires the tumor suppressor protein BRCA1
[22,23]. To test whether phenylbutyrate may affect the
expression of BRCA1 in head and neck cancer cells, we
analyzed the BRCA1 protein levels in mock-treated and
phenylbutyrate-treated cells using Western blot. As can be
seen in Figure 4A, phenylbutyrate reduced expression of
BRCA1 by 48%, 24% and 50% in UM-SCC-1, 6 and 25,
respectively. These results suggest that phenylbutyrate
may sensitize head and neck cancer cells to cisplatin by
interfering with the FA/BRCA pathway through the reduc-
tion of expression of BRCA1
Phenylbutyrate sensitizes head and neck cancer cells by 
targeting multiple pathways
If the cisplatin-sensitizing activity of phenylbutyrate is
chiefly due to the inhibition of the FA/BRCA1 pathway,
then phenylbutyrate should have only limited ability to
sensitize head and neck cancer cell lines that are defective
in the FA/BRCA1 pathway. To test this possibility, we pre-
treated BRCA1-deficient UM-SSC-17B cells [6] with phe-
Cisplatin-induced monoubiquitylation of FANCD2 is not  affected by phenylbutyrate in UM-SCC-1, -6 and -25 cell lines Figure 3
Cisplatin-induced monoubiquitylation of FANCD2 is not 
affected by phenylbutyrate in UM-SCC-1, -6 and -25 cell 
lines. Cells were treated with 2 mM phenylbutyrate (PB) for 
48 hours before adding 5 μM cisplatin and incubated for an 
additional 24 hours. *represents the slower migrating 
monoubiquitylated form of FANCD2.
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Phenylbutyrate abrogates the formation of FANCD2 foci fol- lowing cisplatin treatment Figure 2
Phenylbutyrate abrogates the formation of FANCD2 foci fol-
lowing cisplatin treatment. (A) UM-SCC-6 cells were treated 
with 2 mM phenylbutyrate (PB) for 48 hours before adding 5 
μM cisplatin and incubated for an additional 24 hours. Cells 
were then fixed and stained with anti-FANCD2 antibodies 
and the DNA dye DAPI. (B) The three head and neck cancer 
cell lines were treated as in (A) and FANCD2 foci were 
counted in a blind fashion using a fluorescence microscope. 
Cells containing more than 20 FANCD2 foci are expressed 
as a percentage of 100 cells analyzed for each condition and 
cell line. Error bars represents the standard error of the 
mean from three independent experiments. Statistical analy-
sis using the student's t-test shows that phenylbutyrate signif-
icantly reduced the number of cells with > 20 FANCD2 
nuclear foci. p-values are indicated in the graph. Bars: light 
gray, UM-SCC-1; gray, UM-SCC-6; black, UM-SCC-25.
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nylbutyrate and then treated the cells with cisplatin. Since
these cells are known to be sensitive to cisplatin we used a
lower dose of 2 μM. Although the UM-SSC-17B cells were
fairly sensitive to phenylbutyrate, no sensitization to cis-
platin was apparent suggesting that phenylbutyrate may
only sensitize cells with a functional FA/BRCA1 pathway
(Fig. 5, top panels). However, when these experiments
were performed using another head and neck cancer cell
line (UM-SSC-14A) that also has a defect in the FA/BRCA1
pathway [6], a clear sensitization was observed (Fig. 5,
middle panels). The percentage of apoptosis were 12% in
controls, 14% for phenylbutyrate alone and 21% for cis-
platin alone. When phenylbutyrate and cisplatin treat-
ments were combined the amount of apoptosis rose to
65% which is clearly a more than additive effect. When
the same treatment protocol was used on the FA/BRCA
proficient cell line UM-SSC-6, we observed an additive
effect of the two treatments. Since we used a lower dose of
cisplatin in these experiments, the FA/BRCA-proficient
cells are not as effected by cisplatin as shown in figure 1
where 5 μM cisplatin was used. It can be seen that both of
the FA/BRCA1-defective cell lines show accumulation of
cells in late S-phase and G2/M following cisplatin treat-
ment which is in contrast to the similarly treated FA/
BRCA1-proficient cell line UM-SSC-6. This is to be
expected since the FA/BRCA pathway plays an important
role in the coordination of processing of replication-
blocking lesions. Taken together, the results suggest that
phenylbutyrate do not inhibit the effectivness of cisplatin
toxicity in cell lines with a defective FA/BRCA pathway
which may have important clinical implications. Further-
more, phenylbutyrate may, in addition to inhibiting the
FA/BRCA1 pathway, act on additional targets to sensitize
head and neck cancer cells to cisplatin.
Discussion
Head and neck and ovarian cancers are known to have
heterogeneous clinical responses to the chemotherapeutic
agent cisplatin [1,24,3]. A better understanding of this
variable response as well as the development of novel
strategies to sensitize resistant tumors to cisplatin would
be of great importance for the clinical management of this
disease. We have previously shown that the variability of
the cisplatin response of a subset of head and neck cancer
cell lines is linked to the functional status of the FA/BRCA
pathway [6]. In this study we show that the HDAC inhib-
itor phenylbutyrate sensitizes cisplatin-resistant head and
neck cancer cell lines to cisplatin. This sensitization
appeared to be due to the abrogation of the FA/BRCA
pathway by phenylbutyrate as well as through a FA/
BRCA1-independent mechanism. Specifically, we show
that phenylbutyrate inhibits the formation of FANCD2
nuclear foci after cisplatin treatment and this inhibition
correlates to a down regulation of the tumor suppressor
BRCA1.
There is currently great interest in HDAC inhibitors as
anti-cancer agents [25,26]. The mechanisms for the anti-
tumor activities of HDAC inhibitors include induction of
apoptosis, cell cycle arrest, cell differentiation, and abro-
gation of tumor angiogenesis and invasion [26]. We have
previously shown that the HDAC inhibitor phenylbu-
tyrate down-regulates the anti-apoptosis protein Bcl-XL
and the DNA-dependent protein kinase (DNA-PK)
involved in double strand break repair and cellular stress
signaling [16]. The consequence of the down-regulation
of these proteins should lead to the lowering of the apop-
totic threshold and inhibition of double strand break
repair and thus phenylbutyrate and other HDAC inhibi-
tors may have sensitizing properties when combined with
radiotherapy or chemotherapeutic agents [26]. The results
from this study concur with a sensitizing function of phe-
nylbutyrate when combined with cisplatin. Measuring cell
viability/proliferation, apoptosis and clonogenic survival
revealed a more than additive effect when combining phe-
nylbutyrate and cisplatin on head and neck cancer cell
lines (Fig. 1). Thus, phenylbutyrate may be a useful agent
to sensitize recurrent cisplatin-resistant head and neck
tumors to cisplatin chemotherapy.
We recently showed that a subset of cisplatin-sensitive
head and neck cancer cell lines are defective in cisplatin-
mediated induction of FANCD2 nuclear foci [6]. In this
study we show that phenylbutyrate abrogated the forma-
tion of FANCD2 nuclear foci following cisplatin treat-
ment (Fig. 2). The formation of FANCD2 nuclear foci is
thought to be essential for the proper processing of inter-
strand cross links during S-phase [4,5,27] and thus, the
abrogation of FANCD2 foci formation by phenylbutyrate
pretreatment is probably responsible for the cisplatin-sen-
Phenylbutyrate down-regulates BRCA1 expression in head  and neck cancer cell lines Figure 4
Phenylbutyrate down-regulates BRCA1 expression in head 
and neck cancer cell lines. Cells were treated with 2 mM 
phenylbutyrate (PB) for 3 days before the cells were har-
vested and the levels of BRCA1 protein analyzed with West-
ern blot. The relative amount of BRC1 protein in the 
phenylbutyrate-treated samples is expressed as a fraction of 
the BRCA1 protein level in untreated controls.
β-actin
SCC-25
+++ PB
BRCA1
SCC-6 SCC-1
0.52 0.76 0.50Molecular Cancer 2008, 7:24 http://www.molecular-cancer.com/content/7/1/24
Page 6 of 9
(page number not for citation purposes)
sitizing effect of phenylbutyrate in these cells. We also
show that phenylbutyrate can sensitize FA/BRCA1-defi-
cient head and neck cancer cells suggesting additional tar-
get for cisplatin sensitization by phenylbutyrate. It is
possible that the cisplatin-sensitizing effect of phenylbu-
tyrate is related to its role in targeting the expression of the
apoptosis-antagonist Bcl-XL [16].
How does phenylbutyrate interfere with the formation of
FANCD2 nuclear foci? A required step in order for
FANCD2 proteins to form nuclear foci is that they become
monoubiquitylated at the lys561 residue by the FA
nuclear complex, consisting of at least eight different FA
proteins [4,5,27]. When cisplatin-induced monoubuityla-
tion of FANCD2 was analyzed for the three head and neck
Phenylbutyrate acts on multiple targets to sensitize head and neck cancer cells to cisplatin Figure 5
Phenylbutyrate acts on multiple targets to sensitize head and neck cancer cells to cisplatin. Top panel: BRCA1-defective UM-
SSC-17B cells [6] were mock treated for 5 days (control), treated with 2 mM phenylbutyrate for 5 days (phenylbutyrate), 
treted with 2 μM cisplatin for 3 days (cisplatin) or treated with 2 mM phenylbutyrate for 5 days and 2 μM cisplatin for the last 
3 days (PB+cis). At the completion of the treatment, both floating and attached cells were collected and analyzed by flow 
cytometry. Middle panel: same as above but using the FA/BRCA1-defective UM-SSC-14A cells [6]. Lower panel: Same as above 
but using the FA/BRCA1-proficient cell line UM-SSC-6 [6]. Note that the FA/BRCA1-defective cells appear to struggle through 
late S-phase as evidenced by gradual accumulation of cells in later stages of S-phase while the proficient UM-SSC-6 cell line do 
not show this accumulation. The percentages of sub-G1 DNA-containing cells (apoptotic cells) are presented in each panel.
UM-SSC-17B
UM-SSC-14A
UM-SSC-6
DNA content (PI)
N
u
m
b
e
r
 
o
f
 
c
e
l
l
s
control phenylbutyrate cisplatin PB+cis
1% 6% 5% 11%
2% 17% 5% 15%
12% 14% 21% 65%Molecular Cancer 2008, 7:24 http://www.molecular-cancer.com/content/7/1/24
Page 7 of 9
(page number not for citation purposes)
cancer cell lines, we did not observe any inhibiting effect
of phenylbutyrate (Fig. 3). Thus, phenylbutyrate does not
appear to interfere with the FA/BRCA pathway by inhibit-
ing the monoubiquitylation of FANCD2. Another
requirement for the formation of FANCD2 nuclear foci is
that the cells harbor wild-type BRCA1 [23,22]. In a previ-
ous study we showed that cisplatin-sensitive cell lines hav-
ing a non-functional FA/BRCA pathway were BRCA1
defective [6]. BRCA1-deficient cells are known to be
hypersensitive to cisplatin [28-30] while BRCA1 over-
expression has been shown to lead to increased resistance
to cisplatin [31]. In this study we show that phenylbu-
tyrate treatment leads to a down-regulation of BRCA1 in
all three head and neck cancer cell lines tested (Fig. 4).
Thus, the down-regulation of BRCA1 by phenylbutyrate
may partially explain the abrogation of cisplatin-induced
FANCD2 foci formation and the cellular sensitivity to cis-
platin. We also show that phenylbutyrate must target
other pathways in addition to the FA/BRCA1 pathway
since the FA/BRCA1-defective cell line UM-SSC-14A was
effectively sensitized to cisplatin by phenylbutyrate (Fig.
5).
Cisplatin is one of the most commonly used chemothera-
peutic agents available today for the treatment of various
malignancies [1,2]. However, its normal tissue toxicities,
variable tumor responses and the selection for cisplatin-
resistant cancer cells in reoccurring tumors limit the clini-
cal usefulness of cisplatin. Recent efforts have been
focused on screening for agents that sensitize tumor cells
to cisplatin by inhibiting the FA/BRCA pathway [12]. One
lead compound that interfered with cisplatin-induced
FANCD2 monoubiquitylation and sensitized breast and
ovarian cancer cells to cisplatin was the natural and rela-
tively non-toxic compound curcumin. Our study identi-
fies the HDAC inhibitor phenylbutyrate as an additional
low toxicity agent that sensitizes cancer cells to cisplatin
by interfering with the FA/BRCA pathway. Although fur-
ther studies are needed to in more detail investigate the
mechanisms responsible for the phenylbutyrate-induced
abrogation of the FA/BRCA pathway, BRCA1 down-regu-
lation and cisplatin-sensitization, our study opens up the
possibility that phenylbutyrate could be used to sensitize
cisplatin-resistant head and neck tumors in a clinical set-
ting.
Methods
Cell lines and treatments
The head and neck cancer cell lines UM-SCC-1, -6, -25
were made available to us from the University of Michigan
Head and Neck spore program. These cell lines were estab-
lished from various anatomical locations of head and
neck patients. Cisplatin-sensitivity based on the MTT
assay has been previously assessed in these cell lines and
ID50 for these cell lines were found to be 14.0, 36.7, 18.7
μM respectively [24]. The cells were grown in Dulbecco's
modified Eagle's medium supplemented with 10% heat
inactivated fetal bovine serum, penicillin/streptomycin in
a humidified 5% CO2  incubator at 37°C. Cells were
treated with 2 mM sodium phenylbutyrate (Scandinavian
formulas, PA) for 48 hours and with 5 μM cisplatin
(CDDP) (Sigma Chemicals, MO) and incubated for 72
hours.
Cell proliferation Assay (WST-1 assay)
Exponentially growing UM-SCC-1, -6, -25 cell lines were
plated in 96 well plates at a density of 10,000 cells per well
and incubated in DMEM at 37°C overnight. Cells were
then treated with 2 mM phenylbutyrate for 5 days, 5 μM
cisplatin for 3 days or the combination of the two. At the
completion of the 5 day incubation, 10 μl of cell prolifer-
ation reagent WST-1 (Roche, IN) was added into media in
each well and the cells were incubated for 2 hr at 37°C.
The absorbance (OD) of each well was determined with a
spectrophotometer reading at a wavelength of 490 nm.
Absorbance (OD) is assumed to be directly proportional
to the number of viable cells.
Flow cytometric analysis of apoptosis
Determination of the percentage of apoptosis induced fol-
lowing cisplatin treatment was performed as previously
described [14,32]. Cells were treated with 2 mM phenyl-
butyrate for 5 days, 5 μM cisplatin for 3 days or the com-
bination of the two. After incubation at 37°C, both
floating and attached cells (trypsinized) were collected by
centrifugation (1500 rpm for 5 minutes) and rinsed with
PBS twice. To fix the cells, 500 μl of ice-cold 70% ethanol
was added under mixing. After fixing cells for 30 minutes,
cells were collected by centrifugation at 1500 rpm and
rinsed with PBS twice. Cell pellets were resuspended in
500 μl of propidium iodide (PI) and incubated for 30
minutes at 4°C to stain cellular DNA. Cells with sub-G1
content of DNA were scored as apoptotic using flow
cytometry (Coulter Elite ESP Cell sorter, FL) and the Mul-
ticycle software package (Phoenix Flow Systems, CA).
Clonogenic survival assay
Cells were treated with 2 mM phenylbutyrate for 5 days, 5
μM cisplatin for 3 days or the combination of the two. At
the completion of the 5 day incubation, cell were
trypsinized and seeded in 60 mm plates at a low density
(500 cells/dish) and cultured for 14 days in a humidified
5% CO2 incubator at 37°C. The cells were then rinsed
with PBS and fixed and stained in a solution containing
0.25% crystal violet and 10% formalin (35% v/v) in 80%
methanol for 15 minutes. Colonies were then counted
and values are expressed as the fraction of cells surviving
and normalized to the surviving fraction of control, which
was set to a value of 100%.Molecular Cancer 2008, 7:24 http://www.molecular-cancer.com/content/7/1/24
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Immunoblotting
Cells were lysed with NP40 buffer (150 mM NaCl, 1%
NP-40, 50 mM Tris (pH:8.0)), boiled for 5 min and sub-
jected to 6% polyacrylamide SDS gel electrophoresis. After
electrophoresis, proteins were transferred to Immobilon-
P or Immobilon-FL transfer membranes (Millipore). The
membranes were then blocked with 5% nonfat dried milk
in TBS-T (50 mM Tris-HCl, [pH8.0], 150 mM NaCl, 0.1%
Tween 20) and then incubated with primary antibodies
diluted in Universal Antibody Buffer (30% BSA, 0.2%
NaH3, 1% goat serum in TBS-T). The rabbit anti-FANCD2
antibodies (GeneTex, TX) were used in a 1:1000 dilution
and the mouse anti-BRCA1 antibodies (Santa Cruz Bio-
technology, CA) were used in a 1:100 dilution. After incu-
bation with primary antibodies overnight at 4°C,
membranes were washed with TBST and then incubated
with secondary horseradish peroxidase-conjugated goat
anti-rabbit or anti-mouse antibodies (Sigma, MO) at a
1:2000-fold dilution for 1 hr at room temperature. After
rinses with TBS-T, immunoblotted proteins were captured
on film by chemiluminescence.
Immunofluorescence microscopy
Head and neck cancer cells were seeded on glass coverslips
and incubated overnight before being treated with 2 mM
PB for 3 days, 5 μM cisplatin for 24 hours or the combina-
tion of the two. Cells were then rinsed with PBS three
times and fixed with 4% paraformaldehyde in PBS for 20
minutes at 4°C. The fixed cells were permeabilized with
2% Triton-X-100 in PBS for 8 minutes on ice. After block-
ing in Universal Antibody Buffer (30% BSA, 0.2% NaH3,
1% Goat serum in TBS-T) for 30 minutes at room temper-
ature, anti-FANCD2 and/or anti-BRCA1 antibodies were
added at dilutions of 1:200 and 1:100, respectively. After
1 hr incubation at 37°C, cells were washed three times
with PBSBT (PBS, 0.5% BSA, 0.05% Tween 20) and then
incubated with rabbit AlexarFluor555 (red) and/or mouse
AlexaFluor 488 (green) for 1 hr at 37°C. After incubation,
cells were rinsed with PBSBT three times. Glass coverslips
were mounted in Vectashield containing DAPI. Images
were captured on a Nikon microscope and processed
using Adobe Photoshop software. All the quantification
of FANCD2 foci was performed in a blind fashion.
Abbreviations
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